



---

FOR IMMEDIATE RELEASE

***First patient enrolled in Registration Study of  
Natulan® for patients with advanced Hodgkin's lymphoma in China***

Hong Kong, Jan 3, 2017—Lee's Pharmaceutical Holdings Limited (Main Board Stock Code: 0950; Website: [www.leespharm.com](http://www.leespharm.com)) today announced that the first patient has been enrolled in a registration study of a product from Lediant Biosciences S.A., Natulan® (Procarbazine Hydrochloride Capsule), for the treatment of advanced Hodgkin's lymphoma in China.

Natulan® (procarbazine) in combination chemotherapy is suitable for the treatment of Hodgkin's lymphoma and certain brain cancers (such as glioblastoma multiforme). It is a member of a group of medicines called alkylating agents. It has originally been developed by Hoffmann-La Roche, which first filed a patent claiming its preparation process and its use. The drug (Matulane®) gained FDA approval in the US in July 1969.

This clinical trial is designed as a confirmatory open-label, randomized, controlled, multicenter study. It is led by more than 10 hospitals and the principal investigator is Professor Jun CHU from Beijing Cancer Hospital.

Aim of this trial is to observe and compare the overall response rate (ORR) of baseline BEACOPP and ABVD regimens for patients with advanced Hodgkin's lymphoma and evaluate the safety of Natulan® in Chinese patients with advanced Hodgkin's lymphoma. The study plans to enroll a total of 184 patients and the first patient of this study was enrolled on 29 December 2016.

"We are thrilled of reaching this important milestone for Natulan® in China which is one of the products in our oncology product portfolio. We are dedicated to the oncology area in China, and this is the validation of our commitment to the oncology disease. We are looking forward to the successful completion of the study," stated Dr. Benjamin Li, the Chief Executive Officer of the Group.

### **About Hodgkin's Disease**

Hodgkin's lymphoma — formerly known as Hodgkin's disease — is a cancer of the lymphatic system, which is part of your immune system. In Hodgkin's lymphoma, cells in the lymphatic system grow abnormally and may spread beyond the lymphatic system. As Hodgkin's lymphoma progresses, it compromises your body's ability to fight infection. Hodgkin's Lymphoma can affect the lymph nodes, spleen, bone marrow, and other internal organs. Hodgkin's lymphoma is one of two common types of cancers of the lymphatic system. The other type, non-Hodgkin's lymphoma, is far more common.

### **About Leadiant Biosciences S.A. (Leadiant Biosciences)**

**Leadiant Biosciences** is an R&D Company of the sigma-tau Group specialized in the development of novel and innovative drugs. The company focuses on haematology-oncology. It offers therapeutics for disease areas, including acute lymphoblastic leukaemia, severe combined immunodeficiency disease, cystinosis, cerebrotendinous xanthomatosis, Hodgkin lymphoma, and lymphomatous meningitis. The company was incorporated in 2006 and is headquartered in Windsor, United Kingdom. It has manufacturing plants in Europe and the United States; and research and development sites in Switzerland and the United States. Additional information is available at [http://www.sigmatau.com/about/about\\_group.asp](http://www.sigmatau.com/about/about_group.asp)

### **About Lee's Pharmaceutical Holdings Limited (Lee's Pharm)**

**Lee's Pharm** is a research-based, biopharmaceutical company listed in Hong Kong with over 20 years of operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets 15 products in China. Lee's Pharm focuses on several key disease areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology and others. It has more than 30 products under different development stages stemming from both internal R&D efforts as well as from the recent acquisition of licensing and distribution rights from various U.S., European and Japanese companies. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information is available at <http://www.leespharm.com>.

***Safe Harbor Statement***

*The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*